Grassley gambles on drug price bill despite GOP doubts

Grassley gambles on drug price bill despite GOP doubts
© Greg Nash

Senate Finance Committee Chairman Chuck GrassleyCharles (Chuck) Ernest GrassleyThe Hill's Morning Report — Sponsored by AdvaMed — House panel delays impeachment vote until Friday The Hill's Morning Report - Sponsored by AdvaMed - House panel expected to approve impeachment articles Thursday Horowitz did not find evidence Obama asked for probe of Trump MORE (R-Iowa) is pushing forward with a bipartisan deal to lower drug prices this week despite objections from some members of his own party and a tough road ahead.

The Finance Committee will vote on the deal between Grassley and Sen. Ron WydenRonald (Ron) Lee WydenThe Hill's Morning Report — Sponsored by AdvaMed — House panel delays impeachment vote until Friday Senators zero in on shadowy court at center of IG report Trump administration approves Medicaid work requirements in South Carolina MORE (Ore.), the panel's top Democrat, on Thursday, setting up a closely watched vote for Republican senators.

Many GOP senators are objecting that the plan is too close to price controls for drugs, which Republicans have traditionally opposed.

ADVERTISEMENT

The concerns from within the GOP ranks make it less likely that Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellSherrod Brown backs new North American trade deal: 'This will be the first trade agreement I've ever voted for' McConnell: Bevin pardons 'completely inappropriate' House panel to hold hearing, vote on Trump's new NAFTA proposal MORE (R-Ky.) will bring the bill up for a vote in the full Senate, given he has been reluctant to vote on issues that split his caucus, particularly with a presidential election approaching.

But the announcement from Grassley and Wyden of a deal on Tuesday is a step forward, and the White House made favorable comments on Tuesday, which could help ease GOP lawmakers’ concerns.

The bill's most contentious measure imposes a new limit on price increases in Medicare's prescription drug program, called Part D, forcing drug companies to pay money back if prices rise faster than inflation. The measure also caps Medicare beneficiaries' out-of-pocket costs.

GOP lawmakers could face a tough decision.

In a negative sign for the deal’s chances, Sen. John ThuneJohn Randolph ThuneTrump scramble to rack up accomplishments gives conservatives heartburn House GOP lawmaker wants Senate to hold 'authentic' impeachment trial Republicans consider skipping witnesses in Trump impeachment trial MORE (R-S.D.), the Senate’s No. 2 Republican, told reporters Tuesday he has concerns with the new limits on price increases in saying they are a departure from “free market forces.”

“I suspect I’m not the only one who [has] concerns,” Thune said.

ADVERTISEMENT

But in a positive sign, the White House praised the measure.

“We will work with Senators to ensure this proposal moves forward and advances the President’s priority of lowering drug prices even further and increasing transparency in healthcare for the benefit of all Americans,” said White House spokesman Judd Deere.

Grassley is touting the analysis of the measure from the nonpartisan Congressional Budget Office (CBO) to try to win over Republican senators.

The CBO found that the measure will save taxpayers more $100 billion over a 10-year period. It will also lower out of pocket costs for Medicare beneficiaries by $27 billion and lower premiums by $5 billion according to the CBO.

“I think it’s moving in a positive direction,” said Sen. John CornynJohn CornynTrump scramble to rack up accomplishments gives conservatives heartburn On The Money: Trump, China announce 'Phase One' trade deal | Supreme Court takes up fight over Trump financial records | House panel schedules hearing, vote on new NAFTA deal On The Money: Lawmakers strike spending deal | US, China reach limited trade deal ahead of tariff deadline | Lighthizer fails to quell GOP angst over new NAFTA MORE (R-Texas). “The CBO score was certainly encouraging.”

But other GOP senators sounded a less positive note.

“I still have some concerns, but I hope we can work it out,” said Sen. Pat RobertsCharles (Pat) Patrick RobertsLankford to be named next Senate Ethics chairman The Hill's Morning Report - Intel panel readies to hand off impeachment baton The job no GOP senator wants: 'I'd rather have a root canal' MORE (R-Kan.). Asked if he could vote for it on Thursday, Roberts said, “We’ll see.”

Sen. Rob PortmanRobert (Rob) Jones PortmanOn The Money: Trump, China announce 'Phase One' trade deal | Supreme Court takes up fight over Trump financial records | House panel schedules hearing, vote on new NAFTA deal Here are the Senate Republicans who could vote to convict Trump Lawmakers call for investigation into program meant to help student loan borrowers with disabilities MORE (R-Ohio) also said he wants changes.

Grassley's bill can also expect fierce pushback from drug companies, who have long been a powerful force in Washington.

Drug companies staunchly oppose the deal, and the pharmaceutical lobby was whipping votes against the deal on Tuesday, industry lobbyists said.

Steve Ubl, the CEO of the Pharmaceutical Research and Manufacturers of America, warned that the measure would impose “price controls” and siphon billions of dollars away from research and development by drug companies.

President TrumpDonald John TrumpDemocrats ask if they have reason to worry about UK result Trump scramble to rack up accomplishments gives conservatives heartburn Seven years after Sandy Hook, the politics of guns has changed MORE’s attention to the bill will be a key factor. If he leans in and pressures McConnell to bring it up for a vote, it would improve the measure’s chances.

ADVERTISEMENT

Trump has made lowering drug prices a priority and opened the door to working with Democrats on the issue. The administration's own efforts to lower drug costs have seen mixed results, leaving the president and allies eager for a legislative win on the issue.

But there will be competition for Trump's support, in particular from a rival drug pricing bill in the House.

Speaker Nancy PelosiNancy PelosiTrump scramble to rack up accomplishments gives conservatives heartburn Sherrod Brown backs new North American trade deal: 'This will be the first trade agreement I've ever voted for' Overnight Health Care — Presented by That's Medicaid — Turf war derails push on surprise medical bills | Bill would tax e-cigarettes to pay for anti-vaping campaign | .5M ad blitz backs vulnerable Dems on drug prices MORE’s (D-Calif.) office said Monday that it will unveil House Democrats’ own drug pricing bill in September.

That measure will go farther than the Senate bill by allowing Medicare to negotiate drug prices, a measure that has long been a top priority for Democrats but that is largely opposed by Republicans.

Pelosi aide Wendell Primus said Monday that he is “still very optimistic” that Trump will sign on to what House Democrats are working on.

In the upper chamber, Sen. Lamar AlexanderAndrew (Lamar) Lamar AlexanderTrump scramble to rack up accomplishments gives conservatives heartburn Overnight Health Care — Presented by That's Medicaid — Turf war derails push on surprise medical bills | Bill would tax e-cigarettes to pay for anti-vaping campaign | .5M ad blitz backs vulnerable Dems on drug prices Turf war derails bipartisan push on surprise medical bills MORE (R-Tenn.), chairman of the Senate Health Committee, and Sen. Patty MurrayPatricia (Patty) Lynn MurraySenate confirms Trump's nominee to lead FDA Overnight Health Care — Presented by That's Medicaid — Deal on surprise medical bills faces obstacles | House GOP unveils rival drug pricing measure ahead of Pelosi vote | Justices to hear case over billions in ObamaCare payments Obstacles remain for deal on surprise medical bills MORE (D-Wash.) are also working on their own package to lower health care costs.

ADVERTISEMENT

Trump’s support is far from assured, though, and getting either the House bill or a Senate bill through the full upper chamber will be an extremely tough task.

There is also pressure from the left, especially in the House, to make the efforts even stronger.

In the Senate, progressive Sen. Sherrod BrownSherrod Campbell BrownSherrod Brown backs new North American trade deal: 'This will be the first trade agreement I've ever voted for' Trump trade deal likely to sow division in Democratic presidential field On The Money: Pelosi, Trump tout deal on new NAFTA | McConnell says no trade vote until impeachment trial wraps up | Lawmakers push spending deadline to Thursday MORE (D-Ohio) said the Grassley–Wyden deal is “a start” but said he would like it to go further.

“It’s a start, but you can’t do this right unless you have direct negotiation with the drug companies,” Brown said Tuesday.

“I think they're making progress. I appreciate the work Wyden did on the bill, I think Grassley made some progress here," he continued. "But I'm going to look at it and understand it better.”